Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDUCE dexamphetamine for cocaine use disorder in patients receiving methadone
2023-505556-21-00Phase 3Suspended
- Sponsor
- Parnassia Groep
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cocaine use disorder (CUD) comparing Dexamphetamine sustained-release with Placebo (2 arms). Primary endpoints: Days of cocaine abstinence during weeks 21 to 24 and Good or improved overall health status. Started Mar 2026; status: suspended.
02
Drugs
dextroamphetamine
03
Conditions
cocaine use disorder (CUD)
Beyond the preview
Go deeper on 2023-505556-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505556-21-00.